Key Highlights
● Third-quarter Revenue rose 8.5% to $716.0 million.
● Net income was $137.5 million, or $4.84 per diluted share.
● Net new Business awards were $873.4 million, up 10.6%.
● Backlog reached $3,167.2 million, up 5.6%.
Medpace Holdings, Inc. (NASDAQ:MEDP), a clinical research organization serving biotechnology and pharmaceutical sponsors, is in focus after its third-quarter 2026 report on October 21 paired solid revenue growth with a notable Capital allocation change. The board terminated its prior repurchase authorization, which had $527.0 million remaining, and approved a new program of up to $1.0 billion through December 31, 2028. With Backlog and new awards both rising, investors are weighing Demand visibility against how the company chooses to deploy its cash.
Latest Company Context
Medpace reported third-quarter revenue of $716.0 million, up 8.5% from $659.9 million a year earlier. Net Income was $137.5 million, or $4.84 per diluted share, compared with $111.1 million, or $3.86. EBITDA rose 16.0% to $172.1 million, a 24.0% margin. Net new business awards were $873.4 million, up 10.6%, and backlog reached $3,167.2 million at September 30, 2026, up 5.6%. The backlog conversion rate, which measures how quickly backlog turns into revenue, was 23.8%. By simple division of awards by revenue, the quarter's implied book-to-bill ratio was roughly 1.22 times, a calculation not reported by the company. No shares were repurchased in the third quarter.
Key Business and index Drivers
For 2026, management guided to revenue of $2.835 billion to $2.855 billion, representing growth of 12.0% to 12.8%, GAAP net income of $514.0 million to $524.0 million, Diluted Earnings per Share of $17.97 to $18.32, and EBITDA of $638.0 million to $652.0 million. These are management projections. The buyback program will be funded from cash on hand and executed at management's discretion, meaning the pace is not fixed.
Clinical research demand is influenced by biotechnology funding conditions, since many Medpace clients are small and mid-sized drug developers, so the pace of new awards can be sensitive to Capital Markets and sponsor spending decisions. Net income growth of about 24% outpaced revenue growth, suggesting Operating Leverage in the period. Backlog growth that trails revenue growth, as it did in the quarter at 5.6% versus 8.5%, may deserve attention because backlog supports future revenue.
What Investors Should Watch
Investors may watch whether net new awards continue to exceed revenue, which would support backlog, and whether cancellations remain manageable. Investors may also look for color on pricing, project timing and the mix of therapeutic areas. The pace of repurchases under the new authorization, particularly given that none occurred in the third quarter, may indicate management's view of its flexibility. Fourth-quarter and full-year results will test the 2026 guidance ranges, and any initial commentary on 2027 may become a catalyst.
Biotechnology funding trends, regulatory developments affecting Drug Development and competition from other contract research organizations could shape outcomes. The company's decision to replace rather than simply extend its authorization may be read as a signal about capital priorities, though the release does not state management's reasoning. Analysts may also assess Margin expansion, as EBITDA grew faster than revenue in the latest quarter.
Capital Allocation Takes a New Turn
Medpace's third quarter showed revenue growth, higher earnings, rising awards and a larger repurchase authorization. Backlog growth slower than revenue growth and sensitivity to biotechnology funding remain points that investors may monitor. Cash generation and the interest earned on cash balances also affect earnings, so changes in rates could influence reported profit. Actual results and the timing of Buybacks could differ from current plans.

_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)



Please wait processing your request...